Edwards Lifesciences Corporation

NYSE EW

Edwards Lifesciences Corporation Revenue for the Trailing 12 Months (TTM) ending September 30, 2024: USD 5.87 B

Edwards Lifesciences Corporation Revenue is USD 5.87 B for the Trailing 12 Months (TTM) ending September 30, 2024, a 0.92% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • Edwards Lifesciences Corporation Revenue for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 5.82 B, a 8.49% change year over year.
  • Edwards Lifesciences Corporation Revenue for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 5.36 B, a 5.29% change year over year.
  • Edwards Lifesciences Corporation Revenue for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 5.09 B, a 16.61% change year over year.
  • Edwards Lifesciences Corporation Revenue for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 4.37 B, a 5.23% change year over year.
Key data
Date Revenue Gross Profit Operating Income EBIT
Market news
Loading...
NYSE: EW

Edwards Lifesciences Corporation

CEO Mr. Bernard J. Zovighian
IPO Date March 27, 2000
Location United States
Headquarters One Edwards Way
Employees 19,800
Sector Health Care
Industries
Description

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Similar companies

PODD

Insulet Corporation

USD 267.04

-0.35%

DXCM

DexCom, Inc.

USD 79.17

-0.84%

SYK

Stryker Corporation

USD 362.80

0.50%

ABT

Abbott Laboratories

USD 113.02

-0.15%

MDT

Medtronic plc

USD 85.25

4.23%

ZBH

Zimmer Biomet Holdings, Inc.

USD 104.71

-0.74%

TNDM

Tandem Diabetes Care, Inc.

USD 35.79

-1.16%

BSX

Boston Scientific Corporation

USD 95.65

1.10%

ALGN

Align Technology, Inc.

USD 210.46

-1.51%

StockViz Staff

January 15, 2025

Any question? Send us an email